Global Alzheimer’s Drugs Market Is Likely To Grow At A CAGR Value Of Around 6.3% By 2028

The global Alzheimer’s drugs market was worth around USD 6,429.5 billion in 2021 and is estimated to grow to about USD 9276.3 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.3 percent over the forecast period. The report analyzes the Alzheimer’s drugs market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Alzheimer’s drugs market.

Alzheimer’s drugs are used in the treatment of people affected with Alzheimer’s and since the instances of people being affected with this are increasing so will the demand for Alzheimer’s drugs as well. Increasing research and development activity, rising awareness of Alzheimer’s, and increasing demand for better treatment are other factors that will propel the Alzheimer’s drugs market potential through the forecast period.

Alzheimer’s has been around for a while and no breakthrough success has been found in the treatment hence this has discouraged multiple companies and led to the discontinuation of clinical trials for Alzheimer’s drugs and hence is having a hampering effect on the global Alzheimer’s drugs market potential.

Alzheimer’s drugs companies are investing in the adoption of advanced technologies to advance their research for Alzheimer’s treatment and this is expected to spawn new opportunities for mergers, collaborations, and partnerships. Increasing support from governments to boost the research and treat this growing disease is also expected to provide incentives to Alzheimer’s drugs manufacturers.

The pandemic of 2020 led to a downfall in the Alzheimer’s drugs market. The sudden emergence of coronavirus infection led to a paradigm shift in the healthcare industry and there was a sudden decline in focus on other diseases. The Implementation of lockdown also hampered research and development activity in 2020 which slowed Alzheimer’s drugs market growth.

The Alzheimer’s drugs market is projected to see steady growth in the post-pandemic era owing to the resumption of normal activity on a global scale. As restrictions are lifted and the infections decrease the focus on other diseases will be back and hence drive the Alzheimer’s drugs market growth through 2028.

The global Alzheimer’s drugs market is segregated based on drug class, distribution channel, and region. Based on distribution channel, the global market is distinguished into Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others. The hospital pharmacy segment is anticipated to have a bright outlook through 2028 owing to rising sales of Alzheimer’s drugs through this channel. Increasing hospitalization will also drive the growth of this segment.

North America is the most lucrative market for Alzheimer’s drugs over the forecast period. High research and development activity in this region and the presence of key pharmaceutical companies are expected to be prime factors driving the Alzheimer’s drugs market potential in North America through 2028. The increasing geriatric population will also be a major factor that will drive the Alzheimer’s drugs market growth over the forecast period. The United States is expected to be the most significant market in this region and is expected to see high demand for Alzheimer’s drugs owing to rising instances of Alzheimer’s in the nation. Increasing investments in the development of Alzheimer’s treatment and supportive government initiatives are also expected to boost Alzheimer’s drugs market potential through 2028.

Key players functioning in the global Alzheimer’s drugs market include Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc, and Teva Pharmaceutical Industries Limited

Recent developments:

• In November 2021,  Brigham and Women’s Hospital based in the state of Boston, United States announced the initiation of a clinical trial that will be testing the efficacy of a newly developed vaccine for Alzheimer's disease that can be administered nasally.
• In October 2021, Salk Institute for Biological Studies based in California, United States announced the start of Phase 1 clinical trial to test the safety of Alzheimer’s drug CMS121 in human use. 

Browse the full “Alzheimer’s drugs Market By Drug class (Donepezil, Galantamine, Rivastigmine, Memantine, Others), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, Others), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028” Report at https://www.zionmarketresearch.com/report/alzheimers-drugs-market

Global Alzheimer’s drugs market is segmented as follows:

By Drug class

• Donepezil
• Galantamine
• Rivastigmine
• Memantine
• Others

By Distribution channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com